| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 237.6 | 207.3 | 237.5 |
| Other income | 7.3 | 5.6 | 3.9 |
| Total income | 244.9 | 212.9 | 241.4 |
| Profit before exceptional items & tax | 22.2 | -5.0 | 19.1 |
| Exceptional items | 0.5 | -7.1 | 0.0 |
| Profit before tax | 22.8 | -12.1 | 19.1 |
| Net profit | 23.8 | -12.6 | 22.3 |
| Operating margin | 9.3% | -5.7% | 7.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +6.70% |
|---|---|
| Revenue, year on year | +0.00% |
NSE results filing, NSE: ORCHPHARMA. Figures extracted from the filing.
Orchid Pharma Ltd: key numbers
- Share price
- ₹1,064.90
- Market cap
- ₹6,377 Cr
- Revenue (annual)
- ₹811.3 Cr
- Net profit (annual)
- ₹20.55 Cr
- P/E (TTM)
- 735.8×Sector 50.4×
- Promoter holding
- 69.84%+0.00% QoQ
- FII holding
- 0.80%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Orchid Pharma Ltd
All →Orchid Pharma Capital Structure Change
Orchid Pharma Limited received trading approval for 4,45,86,052 equity shares issued under its NCLT-sanctioned scheme of amalgamation, effective September 23, 2026.
Orchid Pharma Acquisition
Orchid Pharma purchased land in Patibulum Village, Kancheepuram District. This transaction concludes the previous lease arrangement with DBS Bank regarding the property.
Orchid Pharma Annual Report
Orchid Pharma has filed its Annual Report for the financial year 2025-26, which includes the notice for the company's 33rd Annual General Meeting.
Orchid Pharma Annual General Meeting
Orchid Pharma Limited has issued the notice for its 33rd Annual General Meeting scheduled for September 29, 2026, to conduct ordinary and special business.
Orchid Pharma Management Change
Orchid Pharma Limited announced the redesignation of Mr. Arjun Dhanuka as Executive Director and the appointment of M/s. J Karthikeyan & Associates as Cost Auditors.
Orchid Pharma Board Meeting Outcome
Orchid Pharma appointed a cost auditor and designated Mr. Arjun Dhanuka as a Whole-Time Director. The board also set arrangements for the upcoming 33rd Annual General Meeting.